Results 151 to 160 of about 23,901 (228)

Potent bisphosphonate therapy for preventing fractures after denosumab discontinuation in osteoporosis: A GRADE-assessed systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Shah A, Khan S, Rizvi SVZ, Farhan K, Uddin M, Rizvi SUA, Fatima S, Karan AR, Khalid AA, Ali A, Ahmed S.   +10 more
europepmc   +1 more source

Correction: Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity. [PDF]

Curr Osteoporos Rep
Karam L, Paccou J.
europepmc   +1 more source

Impact of clinical pharmacist-led interventions on denosumab adherence. [PDF]

Arch Osteoporos
Zuschnitt A, Lightheart E, Myers J, Khan AN.   +3 more
europepmc   +1 more source

Efficacy and safety of zoledronic acid versus denosumab in the treatment of primary osteoporosis: a single-center retrospective cohort study. [PDF]

Front Endocrinol (Lausanne)
Li X, Huang K, Zhang L, Shi Y, Zhao J, Li X, Gao J, Zhao D, Wan W.   +8 more
europepmc   +1 more source

Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study. [PDF]

Ther Adv Musculoskelet Dis
Chen M, Lu L, Mao Y, Ji L, Xu J, Chen J, Zhu Y, Yuan J, Chen L, Yu J, Lu Q.   +10 more
europepmc   +1 more source

Histologically Confirmed Brain Metastasis Arising From Giant Cell Tumor of Bone: an Uncommon Entity and a Challenging Condition. [PDF]

Am J Case Rep
Claessens A, Martin S, Thiebaut V, Maillot Baron MH, Sirveaux F, Kieffer A.   +5 more
europepmc   +1 more source

Biphasic remodeling and trabecular-cortical uncoupling in the jawbone during antiresorptive therapy and medication-related osteonecrosis: A quantitative imaging analysis. [PDF]

J Dent Sci
Wei LY, Lee JC, Chiu CM, Kok SH, Lin HY, Chiu WY, Chang HH, Cheng SJ, Lee JJ.   +8 more
europepmc   +1 more source

Age-related differences in BMD response during three years of denosumab treatment. [PDF]

Front Aging
Ishikawa K, Asada T, Richardson W, Marius C, Ishikawa M, Nguyen T, Varnadore P, Tani S, Passias P, Alman BA.   +9 more
europepmc   +1 more source

Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab-Denosumab Therapy for Severe Osteoporosis. [PDF]

Yonsei Med J
Kuwabara A, Inage K, Yamashita M, Orita S, Eguchi Y, Shiga Y, Inoue M, Suzuki-Narita M, Hishiya T, Okuyama K, Tashiro S, Ohyama S, Suzuki N, Iida A, Otake Y, Ohtori S.   +15 more
europepmc   +1 more source

Keeping bone resorption markers very low for 1 year after denosumab prevents bone loss at 2 years: the ReoLaus study. [PDF]

Arch Osteoporos
Liebich G, Lamy O, Pasquier J, Gonzalez-Rodriguez E.   +3 more
europepmc   +1 more source